NIH-CAP 2006-07 Participating Companies - 11/2007
NIH-CAP 2006-07 Participating Companies
|AbleLink Technologies, Inc. |
|Colorado Springs, CO |
|Daniel Davies |
|Tel: 719-592-0347 |
|Email: dan@ |
| |
|AbleLink Technologies™ has pioneered technologies which maximize independence and reduce costs for |
|individuals needing specialized supports to live independently. The HomeLife Technology Suite TM |
|delivers easy to use health care instructions using text, video and audio; provides automated |
|reminders to take medications or perform exercises; tracks activity; and remotely communicates health |
|information. This system enables seniors, their family members or home health care providers to |
|perform health care tasks more accurately, using a unique person-centered approach which does not yet |
|exist in the industry. AbleLink is seeking expansion funding, strategic partners and home health care |
|organizations interested in cost-effective strategies for serving the expanding senior population. |
| |
|Advanced Liquid Crystal Tech, Inc. |
|Summit, NJ |
|Patricia Cladis |
|Tel: 908-273-0187 |
|Email: @ |
| |
|A collaboration of physicists and engineers using state-of-the-art techniques and knowledge to turn |
|theory into practice Our products: 1. Hyperpolarimeter - A tool for measuring the magnetization of |
|gases enabling Magnetic Resonance Imaging (MRI) of empty spaces – (lungs, heart, sinuses etc) and |
|tracking of the uptake of oxygen in the brain and other soft tissues in the body. 2. Hyperpolarizer - |
|A portable, fully automated device for polarizing He3, thus enabling MRI of soft tissues and empty |
|spaces, e.g. lungs, sinuses, etc. Our goal is to partner with an existing manufacturer of MRIs and MRI|
|related products to dominate the Hyperpolarized gas market as it develops. |
| |
|Advanced Liquid Logic |
|Research Triangle Pk, NC |
|Richard West |
|Tel: 919-287-9010 |
|Email: rwest@liquid- |
| |
|Advanced Liquid Logic’s digital microfluidics is a lab-on-a-chip technology based on direct, |
|programmable manipulation of discrete droplets using electrical fields. It enables complex liquid |
|handling to be implemented in software with no pumps, valves, or pipes. The Company has implemented |
|rapid and sensitive clinical chemistry and immunoassays on chip and has demonstrated the feasibility |
|of PCR and DNA sequencing. Ultimately complex test panels will be performed on low-volume samples with|
|a PDA-like instrument. The Company has the team (10 PhD’s) and the patent position (30 patents issued |
|or pending) to succeed and seeks partners to take products to market. |
| |
|Advantagene |
|Waban, MA |
|Estuardo Aguilar-Cordova |
|Tel: 617-916-5445 |
|Email: eaguilar@ |
| |
|Progression and recurrence after initial cancer therapy is a key underserved and unmet medical need. |
|Advantagene is focused on addressing this need through simple products that improve the outcome of |
|standard radiation, surgery or chemotherapy. Advantagene’s lead technology, Gene Mediated Cytotoxic |
|Immunotherapy (GMCI™), generates a patient-specific response from a non-patient-specific product. It |
|generates an in-situ tumor-specific vaccine for a targeted, systemic response against residual tumor |
|cells or occult micrometastases. GMCI™ can be applied to a variety of tumor types. Advantagene has |
|positive results from a completed Phase 2 and multiple Phase 1 human clinical trials. |
| |
|AdviTech, Inc. |
|San Antonio, TX |
|Wesley Krueger |
|Tel: 210-697-0880 |
|Email: wkruegermd@ |
| |
|Advitech, Inc. is a company created to develop technology to prevent spatial disorientation and motion|
|sickness. The company has a product specifically for the aviation industry (i.e. the Avionix device), |
|and a product for other applications where individuals have hypersensitivity to motion sickness (i.e. |
|the X-Motion device). The target market is aviation, with the intent to improve safety and prevent the|
|mishaps secondary to some of the illusions causing spatial disorientation. Hardware and software |
|technology have been developed which provides the pilot with more visual information about his head |
|and body position in space. The hardware is comprised of a heads up display system and the software |
|utilizes an artificial horizon and other lines or symbology to display movement and spatial |
|orientation. For military application, the software technology can be displayed in the standard HUD |
|device to provide synergistic information about his or her orientation in space. Other flight |
|personnel can benefit, because they frequently lack visual reference, as the device can assist them |
|with orientation and prevent the ill effects of motion sickness. |
| |
|America Living Well |
|Princeton, NJ |
|Rick Weiss |
|Tel: 609-497-4600 |
|Email: weiss@ |
| |
|America Living Well will become the leader in community-centric obesity initiatives improving the |
|health of children and adults. ALW is a community health web portal, leveraging: • proprietary and |
|proven web-based health, nutritional and behavioral modification technology; • a robust, scaleable, |
|customizable online platform with social networking and local content; • a rewards system fostering |
|multi-channel revenue streams; • the power of community (business and health system partnerships) |
|achieving sustainable impact. A $500K NIH SBIR grant funded a prototype, Princeton Living Well. The |
|company seeks funding for expansion. Five year goal – over 1000 communities generating significant |
|revenue in multi-billion market. |
| |
|Aphios Corporation |
|Woburn, MA |
|Trevor Castor |
|Tel: 781-932-6933 |
|Email: tcastor@ |
| |
|Aphios Corporation () is developing enabling SuperFluids? technology platforms to |
|improve the discovery of natural therapeutics and manufacturing of rare and complex bioactive |
|molecules, the nanodelivery of small molecules and therapeutic proteins, and the inactivation of |
|viruses in natural and recombinant biologics. SuperFluids? are gases such as carbon dioxide and |
|alcohols like ethanol which, when compressed, exhibit enhanced thermodynamic properties of |
|penetration, selection, solvation and expansion. Utilizing these enabling technology platforms, Aphios|
|is also developing enhanced therapeutics for the prevention and treatment of certain infectious |
|diseases, cancers and CNS disorders from a unique library of marine microorganisms and medicinal |
|plants. |
| |
|Artann Laboratories, Inc |
|Trenton, NJ |
|Noune Sarvazyan |
|Tel: 512-996-8565 |
|Email: nsarvaz@ |
| |
|Artann Laboratories (Artann) is a research and development company with mission to develop and |
|commercialize novel high-tech products and technologies. Patented inventions of Artann include a |
|variety of novel medical imaging modalities: mechanical imaging, new approaches to ultrasonic and |
|magnetic resonance elasticity imaging and shear wave elasticity imaging. Artann has also developed and|
|patented several medical diagnostic devices, including skin elasticity analyzer; muscle water content |
|tester, colonoscopy force monitor, portfolio of scanning bone ltrasonometers, and several applications|
|of the time reversal acoustics. The main focus of company NIH CAP activity is development of FDA |
|application for prostate cancer detection technology. |
| |
|Assenti |
|Louisville, KY |
|John Naber |
|Tel: 502-852-7910 |
|Email: john.naber@louisville.edu |
| |
|Assenti creates new therapeutic management techniques enabled by biosensors. Assenti is currently |
|developing an intraocular pressure (IOP) monitoring system, small enough to be implanted into the eye.|
|The information provided by this system improves glaucoma therapy and prevents blindness. Glaucoma is |
|the second leading cause of blindness in the USA and causes $3 billion is excess costs for Medicare |
|insurance. Assenti is in preclinical trials and seeks to raise $10 million in private equity |
|investments for further system development, clinical trials, and market launch. |
| |
|Barron Associates, Inc. |
|Charlottesville, VA |
|B. Eugene Parker, Jr. |
|Tel: 434-973-1215 |
|Email: parker@ |
| |
|Barron Associates, Inc. is an engineering/scientific R&D and professional technical services company. |
|Since its inception in 1983, Barron Associates has developed applications for commercial and |
|government clients in diverse areas ranging from flight vehicle guidance and control systems to |
|medical devices. Our approach to commercialization of technology is to form joint ventures based, in |
|part, on Barron Associates' SBIR technologies. One technology that the company is presently looking to|
|commercialize is a wireless biosignal monitoring system that can be used, for example, to implement a |
|fully untethered, high-performance (e.g., 16 channels, 2,000 16-bit samples per channel) digital |
|electromyography (EMG) system. |
| |
|Behavioral Research, Inc |
|ALBUQUERQUE, NM |
|Robin Inlander |
|Tel: 505-265-4826 |
|Email: robin@ |
| |
|Behavioral Research, Incorporated (BRI) is a small, for-profit, woman-owned company founded by a M.D.,|
|MPH. BRI's mission is to enhance the well-being of individuals, families and communities through the |
|development and distribution of innovative, customer-driven, research-based interventions in |
|behavioral health. BRI’s interactive, computer-based, Pregnancy Information Program (PIP), funded by |
|NIH/NIDA, is directed at the needs of pregnant woman and their providers. The PIP has been shown to |
|accurately identify behaviors that may adversely affect birth outcomes, engage respondents in making |
|positive changes, provide a powerful timesaving tool for busy clinicians and ultimately save money. |
|BRI seeks strategic partners and customers. |
| |
|BIOMEC Inc. |
|Cleveland, OH |
|Robert Purcell |
|Tel: 216-937-2800 |
|Email: bpurcell@ |
| |
|BIOMEC INC, which began operations in 1998, is focused on the development and commercialization of |
|innovative medical devices. One promising device that is being developed and is nearing |
|commercialization is a low-power, lightweight, portable and non-invasive pneumothorax (collapsed lung)|
|detector. This device fulfills a strong unmet need in the first responder markets, including EMTs, |
|Emergency Physicians, as well as a large Military market. BIOMEC has built multiple prototypes and |
|completed successful clinical testing on the device. BIOMEC is currently finalizing product |
|development and preparing the regulatory trials. BIOMEC is currently seeking additional capital to |
|complete clinical trials, obtain FDA approval and launch the commercial device. |
| |
|BioMed Software Inc. |
|Newton, MA |
|John McCall |
|Tel: 617-694-4460 |
|Email: jmccall@ |
| |
|BioMed Software Inc. is the developer of ManRay - Effective Dose Software. No methodology currently |
|exists for rapid and customizable dose determination for radiographic procedures. We deliver |
|user-friendly software for the calculation of effective patient dose from all diagnostic x-ray |
|procedures. User input, requiring only a few seconds, specifies all characteristics of the photon |
|beam, type of examination, phantom gender and size. Full capability of simulating planar radiography, |
|CT (including non-contiguous slices and gantry tilt) and fluoroscopy (including C-arm and table |
|arrangements) is included. Calculations are performed via Monte Carlo simulation using a |
|state-of-the-art transport code available in the public domain. Simulation times of only a few minutes|
|lead to statistical accuracies of 20,000 extracts, 100,000 purified and semipurified compounds |
|from over 30,000 field collected basidiomycetes and ascomycetes (mushrooms). Most of our collection is|
|from unculturable species. Our compound libraries area rich source of novel compounds, many of then |
|synthesized under conditions of environmental stress. LifePharms is presently screening this natural |
|product library for novel anticancer and antiviral compounds. We are seeking strategic partners to |
|discover lead compounds in additional therapeutic areas including antibacterial, immune suppressants, |
|cholesterol lowering, etc. For more information see . |
| |
|LifeSensors Inc |
|Malvern, PA |
|Tauseef Butt |
|Tel: 610-644-8845 |
|Email: butt@ |
| |
|LifeSensors is a privately held biotechnology company located 35 miles west of Philadelphia. |
|LifeSensors SUMOpro® fusion technology enhances the expression and solubility of difficult to express |
|proteins in E. coli, yeast, insect, and mammalian cells. LifeSensors patented technology is used to |
|express and purify proteins for research, diagnostics and therapeutic use. LifeSensors performs |
|contract expression and purification services. LifeSensors is expressing important families of |
|proteins such as de-ubiquitinases, kinases and GPCRs to develop functional protein arrays for drug |
|discovery, diagnostics and toxicology studies. |
| |
|Lynntech, Inc. |
|College Station, TX |
|Scott McKenzie |
|Tel: 979-693-0017 |
|Email: scott.mckenzie@ |
| |
|Lynntech is a Texas-based technology and commercialization company with over 115 U.S. patents and |
|corresponding foreign filings in numerous areas of innovation. Our current offering focuses on a new |
|therapeutic drug and simple device to treat diverse dermal, ophthalmic, dental and burn wound |
|infections that are increasingly becoming resistant to conventional antibiotics. We have developed a |
|lead compound(s) that have shown specific antimicrobial activity against bacteria, fungi, yeast, and |
|mold without toxic impact on healthy mammalian tissue cells in vitro. This patent pending drug and |
|device utilize photodymanic therapy properties of chemically modified nanostructured fullerenes |
|(a.k.a. buckeyballs) which target pathogens throughout the infection and are activated to a biocidal |
|status locally by targeted ‘white light’. |
| |
|MandalMed, Inc. |
|SAN FRANCISCO, CA |
|Constance John |
|Tel: 415-495-5570 |
|Email: connie@ |
| |
|MandalMed is the first and only source of proprietary human Sertoli cells and is developing both |
|cellular therapy products and reproductive function toxicity assays for the diagnostic research |
|markets. A significant body of data shows that Sertoli cells reduce host rejection of allografted |
|cells during transplantation and increase the growth of certain cells such as neurons. Potentially, |
|these Sertoli cells have multiple treatment applications in important markets including Type 1 |
|diabetes, neurodegenerative diseases, and infertility due to deficiency or malfunctioning Sertolis. |
|MandalMed is seeking seed capital and to establish strategic alliances for development of cellular |
|therapeutics. |
| |
|MBF Bioscience (MicroBrightField, Inc.) |
|Williston, VT |
|Jeffrey Sprenger |
|Tel: 802-288-9290 |
|Email: jeff@ |
| |
|MBF Bioscience provides neuroscience researchers and cell biologists with microscopic image analysis |
|systems and solutions. Our products, Neurolucida® and Stereo Investigator® are used by over 1000 |
|research laboratories worldwide for neuron tracing, brain mapping, stereology and morphometric |
|analysis. AutoNeuron®, a new product developed under SBIR funding, automates the process of |
|reconstructing and analyzing neuron morphology from 3D images. MBF is a privately held, U.S. based, |
|company with offices in Europe and Japan and a dealer network covering East Asia, Australia and South |
|America. |
| |
|Mealtime Partners, Inc. |
|Azle, TX |
|Catherine Wyatt |
|Tel: 817-237-9991 |
|Email: catherine@ |
| |
|Mealtime Partners, Inc. is the developer and manufacturer of the Mealtime Partner Assistive Dining |
|Device. The Mealtime Partner is a new and innovative technology that permits individuals, who |
|otherwise cannot feed themselves, to eat without assistance after they are provided with food. It will|
|provide independence when eating for persons with impairments due to spinal cord injury, cerebral |
|palsy, multiple sclerosis, stroke, muscular dystrophy, birth defects, and old age. The Mealtime |
|Partner provides the foundation for a new industry serving the needs of the rapidly growing population|
|of elderly and disabled individuals who are unable to eat independently. |
| |
|Medical Decision Modeling Inc. |
|Indianapolis, IN |
|Harry J. Smolen |
|Tel: 317-704-3800 |
|Email: smolen@mdm- |
| |
|Medical Decision Modeling Inc.'s mission is to provide products and services that facilitate |
|cost-effective healthcare decisions. MDM's core competency lies in the development of interactive |
|software applications called medical decision models. These models clearly communicate the risks, |
|benefits, and costs of competing courses of care for medical conditions. MDM's target markets include |
|pharmaceutical companies, medical device manufacturers; and healthcare payers, providers, and |
|patients. MDM's corporate objective is to be the world leader in the development and dissemination of |
|medical decision models to payers (and those who market to them, e.g., pharmaceutical and device |
|companies), providers, and patients. |
| |
|Medical Directions, Inc |
|Tucson, AZ |
|John Harris Jr. |
|Tel: 520-722-1970 |
|Email: sharris@md- |
| |
|Medical Directions, Inc (MDI) is a privately-held small business specializing in online medical |
|education. MDI has developed an efficient, proprietary educational development and deployment software|
|platform. It has demonstrated in controlled studies that its educational programs are as effective as |
|live meetings by trained experts. MDI’s programs can be developed and deployed nationally and |
|internationally for a fraction of the cost of live meetings. MDI’s customers include thousands of |
|individual physicians, major academic medical centers, philanthropic organizations, health care |
|delivery systems, government agencies, and other entities seeking to provide effective medical |
|education at a lower cost. |
| |
|MediSpin Inc. |
|New York, NY |
|Brian Shanahan |
|Tel: 212-255-9948 |
|Email: bshanahan@ |
| |
|MediSpin, Inc. is an innovative medical communications company consisting of a team of knowledgeable, |
|experienced, creative professionals dedicated to meeting the educational, training, and marketing |
|needs of diverse healthcare, pharmaceutical, and academic specialists. Currently, MediSpin, working |
|with Duke University under NIMH Phase II grant funding, is developing an Internet-based software |
|prototype designed to assist physicians who treat ADHD children to implement evidence-based treatment |
|procedures. This product is designed to provide community physicians with tools that will allow them |
|to efficiently, effectively, and economically (both in time and cost) treat ADHD children. It will |
|also greatly enhance communication between the physician, parent and teacher. |
| |
|Mi-Co |
|Research Triangle Park, NC |
|Gregory Clary |
|Tel: 919-485-4819 |
|Email: gclary@mi- |
| |
|Mi-Co, the mobile data capture company, provides software to eliminate numerous pains of paper |
|forms-based business processes. Mi-Co’s enterprise Mi-Forms Software System provides flexible |
|electronic forms design for data capture using digital ink and has proven capabilities for handwriting|
|interpretation and verification, data validation and the communication of forms-based data. Mi-Forms |
|supports Tablet PCs, Digital Pens, Pocket PCs, signature capture devices and industry standard |
|software technologies. Mi-Co reaches historically paperwork intensive markets such as the healthcare |
|and government sectors through a growing network of over forty channel partners. |
|mi- |
| |
|MicroMRI Inc |
|Philadelphia, PA |
|Onne Ganel |
|Tel: 215-564-1002*15 |
|Email: oganel@ |
| |
|MicroMRI aims to provide imaging-based monitoring tools which are non-invasive, accurate, |
|readily-available and cost-effective. MicroMRI’s current products deliver microscopic-level images of |
|bone and cartilage architecture for arthritis and osteoporotic disease monitoring. The currently |
|available tools with adequate specificity are invasive: bone biopsies and arthroscopies. MicroMRI |
|delivers non-invasive methods to accurately evaluate these diseases. MicroMRI sells its systems for |
|research and is the world’s only company that provides research services for structural quantification|
|of bone changes during drug treatment in humans for pharmaceutical and academic research. MicroMRI |
|intends to obtain FDA clearance for its systems and market them in clinical markets. |
| |
|Micronics, Inc. |
|Redmond, WA |
|Karen Hedine |
|Tel: 425-895-9197 |
|Email: khedine@ |
| |
|Micronics has developed a unique, proprietary, rapid-test platform that produces sample-to-result |
|analyses in seconds to minutes. Tests are configured as miniaturized (credit card size) disposable |
|devices that can be used at point-of-care when highly sensitive and specific results are needed. |
|Products in development include molecular diagnostics for detection of sexually transmitted diseases, |
|enteric pathogens, fever-causing pathogens, and several rare cancers. An ABO/Rh typing test is also in|
|advanced development. The platform can be adapted to virtually any diagnostic assay where high quality|
|detection reagents exist. Micronics is focused on building strategic partnerships to market these |
|advanced products. |
| |
|MicroStrain Inc |
|Williston, VT |
|Mike Robinson |
|Tel: 802-862-6629 |
|Email: mirobinson@ |
| |
|MicroStrain is a privately held corporation based in Williston Vermont. We produce smart, wireless |
|sensors for strain, displacement & orientation monitoring. Our products are used in automotive, |
|aerospace, military, and medical applications for health monitoring of machines, structures, and |
|devices. Inertia-Link™, is MicroStrain’s latest wireless inertial measurement device. It uses |
|miniature gyroscopes and accelerometers for wearable motion analyses, eliminating the cables |
|associated with traditional motion trackers. On board intelligent processing combined with mobile |
|phone connectivity enable the patient’s biomechanical status to be tracked remotely. MicroStrain is |
|currently seeking partners to transition this technology into key medical monitoring applications. |
| |
|MIDI, Inc. |
|Newark, DE |
|Myron Sasser |
|Tel: 302-737-4297 |
|Email: myron@midi- |
| |
|MIDI Inc., for 18 years, has created and sold a gas chromatography- based system using fatty acid |
|composition for identification of bacteria. The current add-on product is a technique for rapid |
|identification of bacteria direct from blood culture bottles. This 30-minute procedure will be highly |
|competitive with current techniques that typically take one to three days. The savings in time result |
|in shorter hospital stay time for patients and greater precision in choice of antibiotic therapy. |
| |
|Mikro Systems, Inc. |
|Charlottesville, VA |
|Michael Appleby |
|Tel: 434-244-6480 |
|Email: appleby@ |
| |
|Mikro Systems, Inc. develops and supplies high-performance micro devices and systems to customers |
|operating in the fields of: • advanced structures, • biomedicine, • radiation imaging and detection, |
|and |
| |
|Morphonix LLC |
|Sausalito, CA |
|Karen Littman |
|Tel: 415-331-5010 |
|Email: kl@ |
| |
|For the past 17 years, Morphonix LLC has developed innovative programs in new media to better educate |
|and support children. It has released award-winning, entertaining, immersive learning games that make |
|the complex concepts of brain science fun for children and teens. From the acclaimed Journey Into The |
|Brain (for ages 7-11) to the soon-to-be released Neuromatrix (ages 11-14), Morphonix is serving a |
|critical market that everyone can relate to. The huge need for alternative, challenging tools to |
|stimulate kids in schools and at home has put the focus on Morphonix, which now serves consumers at |
|home and schools (with supplemental learning materials). Neuromatrix, bound to be a hit, includes a |
|captivating story and game set in an immersive environment, allowing kids to use their brains to learn|
|about the brain. Morphonix's video games are cool enough to play at home, smart enough to play at |
|school. Morphonix seeks developmental and/or licensing partners to take the rich content and strong |
|titles it has developed to a new level. |
| |
|Nanogen, Inc. |
|San Diego, CA |
|Dalibor Hodko |
|Tel: 858-410-4718 |
|Email: dhodko@ |
| |
|Potential threat of pandemic flu and emerging infectious diseases emphasized the need for diagnostic |
|systems capable to rapidly recognize diseases with potential epidemiologic consequences. Nanogen is |
|one of the leaders in the microarray-based DNA analysis and its electronic microarray technology |
|offers speed, accuracy and high levels of multiplexing to molecular diagnostics customers. The |
|proposed centrifugal microfluidics based system for sample preparation integrates the electronic |
|microarray detection technology into a portable instrument. A fully developed technology will yield a |
|point-of-care system with exchangeable CDs allowing choice of the pathogen detection panels including |
|respiratory infectious diseases, biological warfare agents or emergent viruses’ panels. |
| |
|Nanoprobes, Incorporated |
|Yaphank, NY |
|Richard Powell |
|Tel: 919-845-6324 |
|Email: rpowell@ |
| |
|Nanoprobes researches and develops novel technology based on the use of metal nano-particles as |
|reagents for the detection and visualization of biological targets. Current commercial products |
|include X-ray contrast agents for MicroCT and research, immunogold reagents and probes, combined |
|fluorescent and gold probes, and ultra-sensitive detection methods for in situ hybridization, |
|microscopic and blotting applications. The company develops technology and reagents for medical |
|imaging and the diagnosis of disease using nanoparticle-based contrast agents and markers, and is also|
|engaged in the development of novel therapeutics based on the enhancement of other therapeutic |
|modalities, such as radiation, by metal nano-particle-based reagents. |
| |
|Neurobiotex, Inc. |
|Galveston, TX |
|Christopher Frederickson |
|Tel: 409-762-0678 |
|Email: c.j.frederickson@ |
| |
|Neurobiotex is a science based company specializing in discovery and invention in the area of zinc in |
|biology. Combining business and scientific expertise we have patents pending on products to measure, |
|control and modulate free zinc. Our research tools, as well as our developing diagnostics and |
|therapeutics focus on early detection and preventive applications in the areas of neurological |
|diseases, cancer and diabetes. We believe this is the future of medicine and that development of our |
|technology shall enhance economic development in our country while significantly decreasing healthcare|
|expenditures. |
| |
|NeuroScript |
|Tempe, AZ |
|Hans-Leo Teulings |
|Tel: 480-350-9200 |
|Email: hlteulings@ |
| |
|NeuroScript is the only company in the world developing and marketing PC software to record and |
|automatically analyze handwriting movements. Our PC software (MovAlyzeR) requires only off-the-shelf |
|hardware. MovAlyzeR makes the seemingly complex measurement and processing of pen movements easy to |
|use after a brief learning period. Currently, MovAlyzeR is used by researchers in kinesiology, |
|experimental psychology, psychiatry, neurology, occupational therapy, aging, handwriting instruction, |
|child development, forensic handwriting analysis, computer science and by university students for |
|their graduation and course projects. Although these markets are small, they will eventually spawn |
|applications satisfying latent needs in several larger groups of health-care professionals or even the|
|general public of consumers. |
| |
|NexBio, Inc. |
|San Diego, CA |
|Mang Yu |
|Tel: 858-452-2631 |
|Email: myu@ |
| |
|In recent years the world has witnessed the escalating outbreaks of avian influenza viruses in humans.|
|The inadequacy of current prophylactic and therapeutic modalities has become all too clear. In |
|response, NexBio, Inc. is developing broad-spectrum therapeutic and prophylactic agents to protect the|
|public from all annual and pandemic variations of influenza, as well as from other life-threatening |
|respiratory viral infections. Our mission is to develop novel, broad-spectrum prophylaxis and |
|therapeutics for the prevention and treatment of serious or life-threatening human respiratory |
|infectious diseases. |
| |
|Nextek Mobility Corporation |
|Albuquerque, NM |
|Brock Roberts |
|Tel: 505-798-9818 |
|Email: Brock@ |
| |
|Nextek Mobility Corporation has developed a new all-wheel drive powered wheelchair with a zero turning|
|radius. The new technology is called PAWS or Parallel- All Wheel Steering and provides excellent |
|maneuverability and incredible off-road performance. Potential customers include power wheelchair |
|users who wish to access outdoor and rough terrain without sacrificing the maneuverability required |
|indoors. |
| |
|Nitrate Elimination Company, Inc |
|Lake Linden, MI |
|Ellen R Campbell |
|Tel: 906-296-1000 |
|Email: ellenr@ |
| |
|NECi, The Nitrate Elimination Company, Inc, is pioneering the migration of enzyme-based analytical |
|methods from research and biomedical fields into the mainstream analytical chemistry community. NECi's|
|introduction of recombinant nitrate reductase (NaR) has made enzyme-based nitrate analysis practical: |
|NaR is produced in commercial quantities with consistent performance properties at affordable cost. |
|NaR replaces the toxic cadmium reagents in use today for nitrate testing in water, public health, |
|agriculture, industry, and the environment. Applications range from test kits for field use to |
|reagents for commercial testing labs. NECi seeks partnering, distribution, and supplier agreements for|
|bulk enzyme and/or for complete test kits. |
| |
|Nonlinear Ion Dynamics, LLC |
|Panorama City, CA |
|Alfred Wong |
|Tel: 818-901-8455 |
|Email: awong@ |
| |
|NID develops a patented PEP technology to efficiently enrich a wide range of stable isotopes for |
|medical, industrial and research applications. Currently, most stable isotopes are imported from |
|foreign countries like Russia. With its advanced technology, NID can address most unmet market needs |
|of stable isotopes, including a wide variety of research isotopes and new medical and industrial |
|stable isotopes. NID provides a US based supply for stable isotopes at competitive price and higher |
|quality. NID aims to become the domestic comprehensive supplier of stable isotopes. |
| |
|O.D.260 Inc |
|Boise, ID |
|Xavier Danthinne |
|Tel: 208-345-7369 |
|Email: xdanthin@ |
| |
|O.D.260 Inc. is an emerging biotech company that develops, manufactures and markets tools for gene |
|technologies. We focus on adenovirus-based gene transfer, and we have unique scientific expertise and |
|technological capabilities in the development of bipartite and conditionally-replicating adenoviruses.|
|The company has recently developed a novel system that will add gutless (helper-dependent) adenovirus |
|construction to its proprietary product offerings. Having provided custom cloning services for more |
|than 5 years, O.D.260 has formed a solid customer base in 3 continents. We are currently looking for |
|partners to extend that service business segment and to market our research kit products |
| |
|Optimum Therapeutics, LLC |
|Columbus, OH |
|Ze Lu |
|Tel: 614-688-5885 |
|Email: zlu@ |
| |
|Optimum Therapeutics, LLC is a small, research-intensive biotech company with a focus on developing |
|products to address unmet needs in the treatment of patients with solid tumors. Currently, products to|
|enhance the effectiveness of chemo- and radio-therapy and to reduce the impact of side effects are in |
|clinical and preclinical stages of development. |
| |
|Organizational Wellness & Learning Systems |
|Fort Worth, TX |
|Joel Bennett |
|Tel: 817-845-2772 |
|Email: owls@ |
| |
|Organizational Wellness & Learning Systems, Inc has developed IntelliPrev™, a patent-pending, |
|web-based platform for HR professionals that enables them to monitor employee perceptions, assess |
|corporate wellness needs, design science-based solutions, shop for wellness vendors, and access tools |
|and training on critical tasks that directly affect their own professional success, including |
|projecting and comparing ROI, securing executive buy-in, preparing their organizations for program |
|delivery, and evaluating program success. IntelliPrev™ is currently seeking “smart” capital, key |
|strategic relationships and one or two outstanding industry professionals to lead this division. |
| |
|ORIGINUS, INC. |
|ANN ARBOR, MI |
|Maria Ines Morano |
|Tel: 734-913-8791 |
|Email: imorano@ |
| |
|Originus Inc. is a biotechnology company found in 2001 by four internationally known scientists from |
|the University of Michigan. With a focus in neuroscience, Originus supplies the Pharma/Biotech |
|industry with high quality cell-based research results and assay products. We specialize in |
|state-of-the-art solid phase transfection using STEP technology, a protein expression protocol, |
|exclusively licensed from the University of Michigan. Using our expertise in complex biological |
|systems, we develop transfection-based assays and functional screening technologies for |
|cost-effective, accelerated, rational and predictive drug discovery. Originus Inc. is seeking |
|Licensing and Partnering with pharmaceutical, biotech or supplier companies. |
| |
|Phase V Pharmaceuticals, Inc. |
|Silver Spring, MD |
|Dwayne Leslie |
|Tel: 301-495-0786 |
|Email: dleslie@ |
| |
|Phase V Pharmaceuticals, Inc. develops new formulations for drugs used to treat central nervous system|
|(CNS) injury. We focus on the special needs of 1.5 million people with a severe traumatic brain |
|injury, spinal cord injury, or cerebral palsy. Our SBIR-supported product improves the care of |
|patients with both spasticity (uncontrolled high muscle tone) and dysphagia (difficulty swallowing) by|
|providing a liquid formulation of baclofen, the first line anti-spastic medication. Phase V's |
|development pipeline addresses over $500 million of the $5 billion spent annually on drugs for this |
|patient population. |
| |
|Phoenix Biosystem, Inc. |
|Pleasanton, CA |
|Kumar Subramanian |
|Tel: 925-998-5075 |
|Email: kumar@ |
| |
|Phoenix Biosystem is developing a proprietary integrated system for automated, small volume, blood |
|sampling and analysis. The best-in-class nano volume sensor based technology provides a platform for |
|highly accurate, cost effective, one step, painless, easy-to-use testing procedures. The product |
|improves patient convenience by automating what traditionally has been a manual, multi-step process of|
|lancing, blood droplet formation, and sample collection. Phoenix Biosystem’s first product will |
|address the unmet self-testing needs of diabetics. The diabetic patient population is stubbornly |
|non-compliant for a combination of reasons including unawareness of the disease, general apathy, cost,|
|and the inconvenience and pain of testing. Phoenix Biosystem's solution of painless, One Step, |
|ease-of-use testing using a very fine lancet, very small drop of blood, and a cost effective automated|
|one step operation will help improve patient compliance substantially. Phoenix Biosystem has raised |
|funds in excess of $2.5 million and has established clinical feasibility of the technology. Phoenix |
|Biosystem is currently seeking to raise $7 Million. The Company expects to use the proceeds to |
|complete the product development and initiate FDA filing. |
| |
|Physical Sciences |
|Andover, MA |
|Mark Druy |
|Tel: 978-738-8195 |
|Email: druy@ |
| |
|Physical Sciences's Inc (PSI) goal is to bridge the gap between the federal government and prime |
|contractors in the research, development and deployment of technology for the U.S. Government. As a 33|
|year old company, PSI has an international reputation for technical excellence and innovation. We have|
|successfully developed and transitioned advanced technologies to support the missions of the |
|Department of Defense, NASA, NIH, and many commercial partners. We are dedicated to the role of |
|applying scientific and engineering innovation to solve technological problems while simultaneously |
|promoting internal product development and ultimate transition to government applications or |
|commercial offering. |
| |
|Phyto-Technologies, Inc. |
|Woodbine, IA |
|Albert Leung |
|Tel: 712-647-2755 |
|Email: ayl@ |
| |
|Phyto-Technologies’ Phyto B/P Profiling™ has successfully bridged the gap between the World’s rich |
|herbal wisdom and modern science. Now, therapeutic, cosmetic and supplement products with the |
|reproducibility, quality control and intellectual property protection commensurate with modern drugs |
|can be developed at a fraction of the latter’s cost. Furthermore, conscientious and knowledgeable |
|researchers and manufacturers who understand the importance of well-defined and appropriately |
|characterized botanical starting materials for achieving reproducible research and quality products |
|can benefit from our unique Representative Botanical Reference/Research Materials™ (RBRM™). We offer a|
|variety of unique market-ready products, developed from our grant-supported research, for licensing |
|and sale. |
|Sitemap | 2007-08 NIH-CAP |
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- viii wastewater facilities by municipality andover
- andover subacute and rehab ii 4 21 20 josh
- nursing home rates njmmis
- barrons magazine the crisis inside america s
- corporate integrity agreement
- nih cap 2005 06 participating companies 11 2007
- downloaded from rootsweb dillman family association
- chapter 2 tax crimes home american inns of court
- the ohio state university home umass amherst
- type document title here
Related searches
- healthways participating fitness centers
- silversneakers participating locations
- 07 career education corporation
- zelle participating banks
- work number participating employer list
- the work number participating employers
- small cap tech companies 2019
- teach grant program participating schools
- fafsa participating schools
- large cap companies in india
- dodm 5205 07 volume 3
- zelle participating credit unions